[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trauma-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trauma-injury":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,49,77,112,137,167,193,224,249,277,302,321,347,368,384,419,450,481,512,532,558,579,608,629,660],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100578511","therapy-dog-visits-for-patients-hospitalized-with-traumatic-injuries-100578511",false,"NCT06812247","Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries","Inclusion Criteria:\n\n* Patients admitted to the Trauma and Acute Care Surgery (TACS) service following a trauma\n* English or Spanish speaking\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Fear of dogs, allergy to dogs\n* Immunocompromised\n* Contact precautions\n* Delirious, intubated, or otherwise unable to consent","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Animal assisted therapy (AAT) with dogs has been shown to be beneficial for a wide range of patients with both acute and chronic illnesses, including spinal cord injuries, heart failure, myocardial infarctions, strokes, cancer, post-traumatic stress disorder, and depression. Studies have also demonstrated that even in healthy adults, the presence of dogs is associated with physiologic changes such as increased pain threshold, decreased blood pressure, and decreased heart rate. However, few studies have investigated the role of AAT in the post-operative course in adults. This study will investigate the impact of therapy dog visits on pain and anxiety scores for trauma patients at Boston Medical Center (BMC).",[26,27,28,29,30],"Trauma Injury","Depression","Anxiety","Anger","Pain",[32,33,34,35],"Therapy dogs","Healing pups","Animal assisted therapy (AAT)","Traumatic injuries recovery","RECRUITING","2026-06-13",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":40},"2025-06-04",{"date":44,"type":20},"2026-12",{"name":46,"class":47},"Boston Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100642234","self-directed-mobile-mindfulness-to-address-icu-survivors-psychological-distress-100642234","NCT07634419","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress: Lift RCT (Lift 3)","Lift 3","Inclusion Criteria:\n\nInclusion criteria present during hospitalization\n\n1. Adult (age ≥18)\n2. Managed in an ICU for ≥24 hours during the time inclusion criterion #3 is met\n3. Serious acute cardiorespiratory condition, defined as ≥1 of the following:\n\n   * mechanical ventilation via endotracheal tube for ≥4 hours\n   * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure\n   * new use of supplemental oxygen ≥6 liters per minute (or increase in baseline continuous oxygen)\n   * use of vasopressors for shock of any etiology\n   * use of inotropes for shock of any etiology\n   * use of pulmonary vasodilators\n   * use of aortic balloon pump or cardiac assist device for cardiogenic shock\n   * use of diuretic intravenous drip\n   * evidence of acute coronary ischemia (i.e., elevated troponin level, supporting EKG changes, unstable angina symptoms documented)\n   * urgent cardiac catheterization\n4. Cognitive status intact\n\n   o No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart\n5. Absence of severe and\u002For persistent mental illness\n\n   o Treatment for severe and\u002For persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \\[as per medical record\\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission\n6. Functional fluency in English or Spanish (i.e., sufficient knowledge of English or Spanish to complete study tasks like watch videos, complete surveys)\n\nInclusion criteria present after hospital discharge (i.e., at the time of arrival home after discharge from the hospital):\n\n1\\. Elevated baseline psychological distress symptoms, defined as a PHQ-9 score ≥5\n\nExclusion Criteria:\n\nExclusion criteria present in the hospital:\n\n1\\. Discharged to a location other than a home setting (e.g., nursing home, long-term acute care facility, inpatient rehabilitation facility)\n\nExclusion criteria present after hospital discharge (i.e., at T1 Data Collection conducted at the time of arrival home from the hospital):\n\n1. Severe psychological distress as assessed by endorsement of active suicidality (see Protection of Human Subjects document for study team management of this finding)\n2. Failure to randomize within 1 month after discharge from the hospital to home\n3. Failure to login to study app and access content within 2 weeks after randomization",{"count":58,"type":20},450,[23],"Serious acute heart and lung illnesses like heart failure, severe COVID, and sepsis often leave survivors struggling not only physically, but also with lasting depression, anxiety, and stress. These problems that are hard to treat because access to mental health care is often limited. To help address this, the researchers created Lift, a fully automated mindfulness program designed with patient input and delivered through a mobile app. The investigators now plan a large, multi-site study to test whether Lift improves mental health and quality of life over six months compared to a critical illness education program called Enlighten Recovery. Overall the goal is to make an easy-to-use, widely accessible program available to people across the U.S., including those who speak Spanish.",[62,63,64,65,66,26],"Critical Illness","Heart Failure","Sepsis","Ards","Pneumonia","NOT_YET_RECRUITING","2026-06-12",{"date":39,"type":40},{"date":71,"type":20},"2026-06-01",{"date":73,"type":20},"2031-05-31",{"name":75,"class":47},"Duke University",3,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100608942","mortality-of-trauma-in-the-intensive-care-unit-100608942","NCT07208110","Mortality of Trauma in the Intensive Care Unit.","Factors Associated With Mortality by Trauma in the Intensive Care Unit in Villavicencio, Colombia. A Trial Based on a Discharge Registry.","MOTRAM-ICU-COL","Inclusion Criteria:\n\n* Admitted to the intensive care unit.\n\nExclusion Criteria:\n\n* None.","15 Years","100 Years",{"count":88,"type":20},500,"OBSERVATIONAL","In this study, it was planned to establish the factors associated with severe trauma discharged from the intensive care unit and mortality. A cross-sectional trial will be conducted to review the ICU discharge database at a two-year interval to review records of trauma admissions patients and compare them with other types of admissions. Participant institutions are general hospitals (public and private) from the Colombian Orinoco region. the prevalence of admission by trauma will also be determined.",[92,93,26,94,95],"Trauma (Including Fractures)","Trauma ICU Patients","Trauma Patients in ICU","Trauma Patients",[97,98,99,100,101,102],"Trauma","Wounds and Injuries","Intensive Care Units","Trauma Registry","Low-Middle Income Countries","Colombia","2026-05-25",{"date":105,"type":40},"2026-05-27",{"date":107,"type":40},"2026-01-30",{"date":109,"type":20},"2028-12",{"name":111,"class":47},"Hospital Departamental de Villavicencio",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100639467","patient-experience-of-older-adults-living-alone-with-injuries-100639467","NCT07610161","Patient Experience of Older Adults Living Alone With Injuries","Patient Experience of Older Adults Living Alone With Injuries and Long-Term Effects of Geriatric Trauma Care Program for Living Alone Older Adults With Injuries","Inclusion Criteria:\n\n1. willing to join this study for 12 weeks\n2. limb injuries,\n3. living alone without any family,\n4. 65 to 74 years old,\n5. independent before an injury,\n6. have a smart phone\n7. be able to communicate in Mandarin\n\nExclusion Criteria:\n\n1. with an ISS greater than 16 (severe injuries)\n2. severe cognitive impairment\n3. severe illness such as organ system insufficiency\n4. diagnosed with depression","65 Years","74 Years",{"count":122,"type":20},110,[23],"This study aims to explore the patient experiences of living alone older adults with injuries, and to examine the effects of a \"Geriatric Trauma Care Program\" in older adults with limb injuries who live alone. A three-year design will be used to reach the purposes of this study. The first stage of this study will use descriptive phenomenology to get patient experiences of living alone older adults with injuries. In the second stage of this study, a two-arm experimental design will be used.",[126,26,127],"Geriatrics","Living Alone","2026-05-20",{"date":105,"type":40},{"date":131,"type":40},"2023-11-22",{"date":133,"type":20},"2026-10-31",{"name":135,"class":47},"Kaohsiung Medical University Chung-Ho Memorial Hospital",2,{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100521496","phase-3-massive-transfusion-in-children-2-a-trial-examining-life-threatening-hemorrhage-in-children-100521496","NCT06070350","Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children","Massive Transfusion in Children: a Platform RCT of Whole Blood Compared to Component Therapy and Tranexamic Acid to Placebo in Life-threatening Traumatic Bleeding","MATIC-2","General Inclusion Criteria:\n\n1. Children, defined as less than estimated18 years of age with traumatic injury\n2. MTP activation for confirmed or suspected active life-threatening traumatic bleeding\n\nAND\n\nConfirmed or suspected active life-threatening traumatic bleeding with at least 2 of 3 of the following criteria:\n\n1. Hypotension for age (\\\u003C 5% tile)\n2. Tachycardia for age (\\>95th % tile)\n3. Traumatic injury with exam findings consistent with severe bleeding (e.g., penetrating injury, hemothorax, distended abdomen with bruising, amputation of limb).\n\nGeneral Exclusion Criteria:\n\n1. Patient with devastating traumatic brain injury not expected to survive due to magnitude of injury (example: Transhemispheric gunshot wound with signs of herniation, GCS score of 3 with fixed and dilated pupils)\n2. MTP activated but no blood products given\n3. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)\n4. Patients who are known or suspected to be pregnant on clinical examination\n5. Known prisoners as defined in protocol\n6. Known ward of the state\n7. Isolated hanging, drowning or burns\n8. Previous enrollment in MATIC-2\n9. Prior study opt-out with bracelet\n\nExclusion Criteria for the TXA\u002FPlacebo Domain\n\n1. Prehospital or pre-enrollment use of TXA\n2. Greater than 3 hours since time of injury\n3. History of seizure after the injury event\n4. Known allergy or hypersensitivity reaction to TXA","17 Years",{"count":147,"type":20},1000,[149],"PHASE3","The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion.\n\nThe primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.",[152,26],"Hemorrhagic Shock",[154,155,156],"Children","Pediatrics","Transfusion","2026-05-07",{"date":159,"type":40},"2026-05-11",{"date":161,"type":40},"2024-11-01",{"date":163,"type":20},"2028-10-01",{"name":165,"class":47},"Philip Spinella",23,{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100538530","human-centered-injury-thrivorship-pathway-for-survivors-of-physical-trauma-100538530","NCT06292039","Human-centered Injury Thrivorship Pathway for Survivors of Physical Trauma","Identifying & Addressing Unmet Needs of Injury Survivors at a Safety Net Hospital in San Francisco","Inclusion Criteria:\n\n* Patient ≥ 18 years old presenting with a physical injury to Zuckerberg San Francisco General Hospital\n* Admitted to the hospital ≥ 24 hours\n* Discharged from the hospital alive\n* San Francisco resident or unhoused in San Francisco\n* Capacity for informed consent\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years old\n* Deceased during index hospitalization\n* Unable to provide informed consent",{"count":7,"type":20},[23],"The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is:\n\n• Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors?\n\nInjury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked.",[178,179,26],"Injury Traumatic","Survivorship",[181,182,183],"Social determinants of health","Community-engaged research","Unmet needs","2026-04-29",{"date":186,"type":40},"2026-05-01",{"date":188,"type":20},"2027-01",{"date":190,"type":20},"2027-06",{"name":192,"class":47},"University of California, San Francisco",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":200,"minAge":17,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":206,"conditions":207,"keywords":213,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100321313","phase-1-bioengineered-penile-tissue-constructs-for-irreversibly-damaged-penile-corpora-100321313","NCT03463239","Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora","Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora","Inclusion Criteria:\n\n1. Males aged 18-60 years.\n2. Acquired structural abnormalities of the corpora cavernosum secondary to trauma, infection, inflammation, or fibromatosis. These abnormalities will be diagnosed by clinical examination, and\u002For ultrasound, and\u002For computerized tomography.\n3. Stable abnormalities - at least 6 months with no pain or changes in deformity.\n4. At least one failed attempt at management by conventional approaches at least 6 months prior to enrollment\n5. Deformities less than 5 cm in length.\n6. Written informed consent obtained prior to participation in the study.\n7. Patients must be available for all follow up visits.\n8. Ability to speak English.\n\nExclusion Criteria:\n\n1. Presence of untreated or incompletely treated urinary tract infection at the time of biopsy.\n2. Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.\n3. Serum creatinine \\> 2.0 mg\u002Fdl or evidence of progressive renal disease.\n4. ALT or AST value \\>1.5 times the upper limit of normal.\n5. Albumin \\\u003C 3.0 g\u002FdL.\n6. Serum direct bilirubin \\>0.3 mg\u002FdL OR total bilirubin \\> 1.4 mg\u002FdL\n7. BM I\\>40 kg\u002Fm2\n8. Uncontrolled diabetes with HbA1C\\>9%. (Subjects with controlled diabetes must be under care of diabetologist with treatment goals consistent with ADA criteria).\n9. Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and\u002For other interventional procedure.\n10. Unstable pulmonary disorders within the past 6 months including dyspnea on exertion, chronic productive cough, pneumonia, hemoptysis, asthma requiring nebulized therapy.\n11. Active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n12. Known to be colonization with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.\n13. Immunocompromised subjects or subjects receiving immunosuppressive agents.\n14. Any history of alcohol and\u002For drug abuse.\n15. Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV). Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.\n16. Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.\n17. Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.\n18. Inability to participate in all necessary study activities due to physical or mental limitations.\n19. Inability or unwillingness to return for all required follow-up visits, for instance life expectancy \\\u003C 1 year, or subject who knows they will be moving out of the country and unable to return for follow-up visits.\n20. Inability or unwillingness to sign informed consent.\n21. Patients requiring concomitant use of or treatment with immunosuppressive agents\n22. Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).","MALE","60 Years",{"count":203,"type":20},10,[205],"PHASE1","The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. Autologous endothelial and smooth muscle cells obtained from enrolled subjects' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa\u002Falbuginea constructs for repair of damaged penile tissues.",[208,209,210,211,212,26],"Urologic Diseases","Male Urogenital Diseases","Penile Diseases","Corpus Callosum Malformation","Corpora Cavernosa; Inflammation",[214],"Autologous tissue engineered corpora","2026-03-26",{"date":217,"type":40},"2026-03-27",{"date":219,"type":20},"2026-10",{"date":221,"type":20},"2030-12",{"name":223,"class":47},"Wake Forest University Health Sciences",{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":48},"100577080","study-of-icg-fluorescence-imaging-in-open-fracture-and-infection-patients-100577080","NCT06793644","Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients","Prospective Observational Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients: Early Comparison With a Novel Imaging Device","cBPI","Inclusion Criteria:\n\n* Patients 18 years of age or older.\n* Open extremity fracture, planning for management with external fixation, internal fixation or joint fusion.\n* Fracture Related Infection, planning for management with debridement and possible removal of hardware.\n* Will have all planned fracture care surgeries performed by a participating surgeon or delegate.\n* Provision of informed consent.\n\nExclusion Criteria:\n\n* Inability of patient to provide informed consent\n* Fracture of the hand.\n* Iodine allergy.\n* Burns at the fracture site.",{"count":203,"type":20},"The purpose of this study is to determine whether an indocyanine green (ICG) fluorescence imaging system (cBPI) can be used to provide surgeons with information about bone health or bone blood flow. This will help surgeons better understand the healing potential of bone and relative risk of complication. This is important to help surgeons select the most appropriate treatment for severe traumatic injuries and infections.",[235,26],"Fractures, Bone",[237,238,239],"Immunofluorescence","Orthopaedic Trauma","Infection","2026-03-17",{"date":242,"type":40},"2026-03-19",{"date":244,"type":40},"2025-06-10",{"date":246,"type":20},"2027-10",{"name":248,"class":47},"Dartmouth-Hitchcock Medical Center",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":255,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":257,"conditions":258,"keywords":262,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":76},"100562665","the-role-of-brain-bone-marrow-gut-interaction-following-major-trauma-100562665","NCT06606119","The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma","Severe Trauma Cohort\n\nInclusion Criteria:\n\n1. All adults (age ≥18).\n2. Blunt trauma with an injury severity score \\> 15 and a long bone or pelvic fracture requiring open reduction internal fixation or intramedullary fixation\n3. Blunt trauma patients with shock, defined by either a systolic BP (SBP) \\\u003C90 mm Hg or base deficit (BD) ≥5 meq or lactate ≥ 2 mmol\u002FL or active red blood cell or whole blood transfusion within 6h or arrival\n\nExclusion Criteria:\n\n1. Patients not expected to survive greater than 48 hours\n2. Prisoners\n3. Pregnancy\n4. Previous bone marrow transplantation\n5. Patients receiving chronic corticosteroids or immunosuppression therapies\n6. Patients with End Stage Renal Disease\n7. Patients with any pre-existing hematological disease\n8. Surgery for repair of injury is greater than seven days after admission to the hospital for trauma\n9. Burn injury greater than 20% TBSA\n\nElective Hip Cohort\n\nInclusion Criteria\n\n1. All adults (age ≥55).\n2. Patient undergoing elective hip repair for non-infectious reasons.\n3. Ability to obtain Informed Consent prior to operation.\n\nExclusion Criteria\n\n1. Patients not expected to survive greater than 48 hours\n2. Prisoners\n3. Pregnancy\n4. Previous bone marrow transplantation\n5. Patients receiving chronic corticosteroids or immunosuppression therapies\n6. Patients with End Stage Renal Disease\n7. Patients with any pre-existing hematological disease",{"count":256,"type":20},275,"Traumatic injury followed by critical illness provokes pathophysiologic changes in the bone marrow and the gut that contribute to persistent anemia and changes in the microbiome which significantly impact long-term recovery. This project will define the interactions between the stress, chronic inflammation, bone marrow dysfunction, and an altered microbiome which will provide a strong foundation for future clinical interventions to help improve outcomes following severe trauma.",[26,97,62,259,260,261],"Microbiome","Chronic Anemia","Acute Blood Loss Anemia",[263,264,265,266,267,268],"Hematopoietic Stem Progenitor Cells","Bone Marrow Failure","Anemia","Gut Microbiome","Inflammation","Dysregulated Stress Response","2026-02-04",{"date":271,"type":40},"2026-02-06",{"date":273,"type":40},"2025-01-24",{"date":163,"type":20},{"name":276,"class":47},"University of Florida",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":16,"minAge":284,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100619376","early-phase-1-iv-injection-of-metoclopramide-with-or-without-dexamethasone-100619376","NCT07343817","IV Injection of Metoclopramide With or Without Dexamethasone","Ultrasonic Evaluation of Metoclopramide With or Without Dexamethasone on Gastric Motility in Traumatic Patients","Inclusion Criteria\n\n* Traumatic patients undergo emergency operations\n* 18-60 years of age\n* 155-180 cm in height\n* Body mass index \\\u003C30 kg\u002Fm2\n\nExclusion Criteria:\n\n* A history of diseases of important organs, such as diabetes, gastro-paresis, liver and kidney dysfunction, and cardiopulmonary insufficiency.\n* Contraindications for metoclopramide or dexamethasone treatment.\n* Taking opioids or drugs that affect gastric motility.\n* A history of esophageal, gastric, or upper abdominal surgery.\n* A need for immediate emergency surgery, resulting in insufficient study time (120 min).\n* Inability of the patient or their family to understand the study protocol.","16 Years","50 Years",{"count":48,"type":20},[288],"EARLY_PHASE1","Reflux and the aspiration of gastric contents have always been important focal points. Previous study stated that trauma is an important factor in aspiration pneumonia.\n\nOften, emergency trauma patients have residual gastric contents due to the ingestion of food before injury, the accidental swallowing of nasal and\u002For oral blood after injury, and delayed gastric emptying due to stress, pain, or the use of opioids.\n\nDuring sedation or general anesthesia, such satiated patients are often at risk of aspiration due to a reduction in lower esophageal sphincter tension and the protective inhibition of the airway reflex.\n\nPerioperative gastric ultrasound can be performed at a bedside ultrasound unit; it can safely, non-invasively, conveniently, and effectively evaluate the fullness of a patient's stomach and the nature of their gastric contents.\n\nIt can also be used in the selection of an appropriate method for the anesthetic induction process and can reduce the risk of vomiting, aspiration, and related complications.\n\nAs a gastric motility-promoting drug, metoclopramide can accelerate gastric emptying.\n\nDexamethasone reduced the incidence of nausea and vomiting and improve gastric motility.",[26],[292],"Poly trauma","2026-01-14",{"date":295,"type":40},"2026-01-15",{"date":297,"type":20},"2026-07-01",{"date":299,"type":20},"2028-04-01",{"name":301,"class":47},"Ahmed Nassar Ibrahim Mohammed",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":21,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":48},"100253423","hematopoietic-stem-cell-dysfunction-in-the-elderly-after-severe-injury-100253423","NCT02577731","Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury","Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury: Chronic Stress and Anemia Recovery Following Major Trauma","Severe Trauma Population\n\nInclusion criteria will be:\n\n1. All adults (age ≥18 to 54)\n2. Blunt and\u002For penetrating trauma resulting in long bone or pelvic fractures requiring ORIF or closed reduction percutaneous pinning (CRPP).\n3. Blunt and\u002For penetrating trauma patient with either:\n\n   1. hemorrhagic shock defined by: i. systolic BP (SBP) ≤ 90 mmHg or ii. mean arterial pressure≤ 65 mmHg or iii. base deficit (BD) ≥ 5 meq or iv. lactate ≥ 2\n   2. Or injury severity score (ISS) greater than or equal to 15.\n4. All adults (age 55 and older) require:\n\n   1. Blunt and\u002For penetrating trauma resulting in log bone or pelvic fractures requiring ORIF or CRPP\n   2. Either hemorrhagic shock defined by: i. Systolic BP (SBP) ≤ 90 mmHg or ii. Mean arterial pressure ≤ 65 mmHg or iii. Base deficit (BD) ≥5 meq or iv. Lactate ≥ 2\n   3. Or Injury Severity Score (ISS) greater than or equal to 15.\n5. Ability to obtain Informed Consent prior to OR repair of injury.\n\nExclusion Criteria will be:\n\n1. Patients not expected to survive greater than 48 hours.\n2. Prisoners.\n3. Pregnancy.\n4. Patients receiving chronic corticosteroids or immunosuppression therapies.\n5. Previous bone marrow transplantation.\n6. Patients with End Stage Renal Disease.\n7. Patients with any pre-existing hematological disease.\n\nElective Hip Repair Population\n\nInclusion criteria will be:\n\n1. All adults (age ≥18)\n2. Patient undergoing elective hip repair for non-infectious reasons.\n3. Ability to obtain Informed Consent prior to operation.\n\nExclusion Criteria will be:\n\n1. Pregnancy.\n2. Prisoners.\n3. Patients receiving chronic corticosteroids or immunosuppression therapies.\n4. History of receiving Chemotherapy or Radiation within the last 6 months\n5. Previous bone marrow transplantation\n\n7\\. Patients with End Stage Renal Disease 8. Patients with any pre-existing hematological disease",{"count":310,"type":20},400,[23],"Traumatic injury is a leading cause of morbidity and mortality in young adults, and remains a substantial economic and health care burden. Despite decades of promising preclinical and clinical investigations in trauma, investigators understanding of these entities is still incomplete, and few therapies have shown success. During severe trauma, bone marrow granulocyte stores are rapidly released into the peripheral circulation. This release subsequently induces the expansion and repopulation of empty or evacuated space by hematopoietic stem cells (HSCs). Although the patient experiences an early loss of bone marrow myeloid-derived cells, stem cell expansion is largely skewed towards the repopulation of the myeloid lineage\u002Fcompartment. The hypothesis is that this 'emergency myelopoiesis' is critical for the survival of the severely traumatized and further, failure of the emergency myelopoietic response is associated with global immunosuppression and susceptibility to secondary infection. Also, identifying the release of myeloid derived suppressor cells (MDSCs) in the circulation of human severe trauma subjects. This process is driven by HSCs in the bone marrow of trauma subjects. Additionally, MDSCs may have a profound effect on the nutritional status of the host. The appearance of these MDSCs after trauma is associated with a loss of muscle tissue in these subjects. This muscle loss and possible increased catabolism have huge effects on long term outcomes for these subjects. It is the investigator's goal to understand the differences that occur in these in HSCs and muscle cells as opposed to non-injured and non-infected controls. This work will lead to a better understanding of the myelopoietic and catabolic response following trauma.",[26],[97],{"date":295,"type":40},{"date":317,"type":40},"2014-01",{"date":319,"type":20},"2027-12-31",{"name":276,"class":47},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":328,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":329,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":48},"100616931","the-effects-of-footplate-stiffness-on-foot-loading-within-carbon-fiber-custom-dynamic-orthoses-100616931","NCT07312032","The Effects of Footplate Stiffness on Foot Loading Within Carbon Fiber Custom Dynamic Orthoses","CDOCFPlate","Inclusion Criteria\n\n* Between the ages of 18 and 65\n* Healthy without current complaint of lower extremity pain, spine pain, open wounds or active infections, or medical or neuromusculoskeletal disorders that have limited their participation in work or exercise in the last 6 months\n* Able to hop without pain\n* Able to perform a full squat without pain\n* Ability to read and write in English and provide written informed consent\n* Ability to fit in a generic sized CDO\n\nExclusion Criteria\n\n* Diagnosed with a moderate or severe brain injury\n* Lower extremity injury resulting in surgery or limiting function for greater than 6 weeks\n* Injuries that would limit performance in this study\n* Diagnosed with a physical or psychological condition that would preclude functional testing (e.g. cardiac condition, clotting disorder, pulmonary condition)\n* Visual or hearing impairments that limit walking ability or limit the ability to comply with instructions given during testing\n* Require use of an assistive device\n* Unhealed wounds (cuts\u002Fabrasions) that would prevent AFO use\n* BMI \\> 40\n* Pregnancy",true,{"count":330,"type":20},20,[23],"Carbon fiber custom dynamic orthoses (CDOs) improve function, reduce pain, and offload the foot and ankle. CDOs include a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that bends to store and return energy, and a semi-rigid carbon fiber footplate. The purpose of this study is to determine the effect of CDO use and CDO footplate stiffness on foot loading, limb mechanics, pain, and comfort.",[26],[335,336,337],"carbon fiber","traumatic injury","ankle foot orthosis","2025-12-29",{"date":340,"type":40},"2025-12-31",{"date":342,"type":40},"2025-12-13",{"date":344,"type":20},"2027-12-01",{"name":346,"class":47},"Jason Wilken",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":354,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":48},"100486596","pathological-myeloid-activation-after-sepsis-and-trauma-100486596","NCT05616130","Pathological Myeloid Activation After Sepsis and Trauma","Pathological Myeloid Activation After Sepsis and Trauma Subtitle: Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis Pathobiology","Trauma population\n\nInclusion Criteria:\n\n1. All adults age ≥ 18 years\n2. Blunt and\u002For penetrating trauma resulting in long bone or pelvic fractures requiring open reduction internal fixation or closed reduction percutaneous pinning\n3. Blunt and\u002For penetrating trauma patient with a. Injury Severity Score (ISS) greater than or equal to 25 b. ISS \\> 15 and one of the following: i. \\> 4 units of packed red blood cell or \\>3 units of whole blood or \\>1500 ml of autogenous blood product in the first 24 hours of admission ii. AIS (acute injury score) \\> 2 spine iii. Shock on arrival (SBP \\\u003C 90)\n\nOR\n\nc. ISS \\> 15 and two of the following: i. Age \\> 55 ii. AIS \\> 2 chest iii. +ethyl alcohol on arrival iv. Any red blood cell transfusion in first 24 hours\n\nExclusion Criteria:\n\n1. Patients not expected to survive greater than 48 hours.\n2. Prisoners.\n3. Pregnancy.\n4. Patients receiving chronic corticosteroids or immunosuppression therapies.\n5. Previous bone marrow transplantation.\n6. Patients with End Stage Renal Disease.\n7. Patients with any pre-existing hematological disease.\n8. Patients deemed to be futile care or have advanced directives limiting resuscitative efforts.\n9. Patients with severe congestive heart failure (NY Heart Association Class IV).\n10. Known HIV infection with CD4+ (clusters of differentiation) count \\\u003C200 cells\u002Fmm3\n11. Chronic liver disease with MELD (Model for End-Stage Liver Disease) score ≥15\n\nElective Hip population\n\nInclusion Criteria:\n\n1. All adults (age ≥18)\n2. Patient undergoing elective hip repair for non-infectious reasons.\n3. Ability to obtain Informed Consent prior to operation.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. Prisoners.\n3. Patients receiving chronic corticosteroids or immunosuppression therapies.\n4. Pre-existing conditions such as pathological fractures, cancer, history of HIV, or history of connective tissue disease.\n5. Previous bone marrow transplantation.\n6. Patients with End Stage Renal Disease.\n7. Patients with any pre-existing hematological disease.\n8. Patients with known active\u002Fsymptomatic COVID-19 (Coronavirus disease).",{"count":355,"type":20},255,"The goal of this observational study is to better understand what happens to circulating blood after a patient experiences severe trauma injury. The main questions it aims to answer are: Is severe human trauma associated with specific patterns of development in the hematopoietic stem cells of these patients? and Does the initial severe trauma injury create immunosuppression and increase risk of in-hospital sepsis? Participants in study will give blood samples and a waste sample of bone marrow at time of operative repair of traumatic orthopedic injuries, supply medical information and participate in surveys and assessments during recovery from their injury(ies). Researchers will compare severe trauma injury patients to elective hip repair patients to see if immunosuppression and specific development patterns occur in the trauma patient versus the otherwise healthy hip surgery patient.",[26,64,358,359],"Immunosuppression","Chronic Critical Illness","2025-12-23",{"date":362,"type":40},"2025-12-26",{"date":364,"type":40},"2022-09-01",{"date":366,"type":20},"2028-09-30",{"name":276,"class":47},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":328,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":375,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":48},"100447784","dysfunctional-myelopoiesis-and-myeloid-derived-suppressor-cells-in-sepsis-100447784","NCT05110937","Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis","Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis Pathobiology Subtitle: Pathological Myeloid Activation After Sepsis and Trauma","Sepsis participant:\n\nInclusion Criteria:\n\n1. age ≥18 years\n2. meets criteria for sepsis\u002Fseptic shock by Sepsis-3 consensus criteria.\n\nExclusion Criteria:\n\n1. have disease states that predispose to significant immune system dysfunction\n2. have comorbidity burden or goals of care that preclude recovery after sepsis. These criteria include:\n\n   a. irreversible shock (death \\\u003C12 hours) b. uncontrollable surgical source of sepsis c. patients deemed to be futile care or have advanced directives limiting resuscitative efforts d. alternative diagnoses causing shock state (e.g., hemorrhage, myocardial infarction or pulmonary embolus) e. known HIV infection with CD4+ count \\\u003C200 cells\u002Fmm3 g. severe traumatic brain injury with unencumbered assessment of GCS equaling 3 on admission to the intensive care unit.\n3. known pregnancy\n4. enrollment \\>96 hours after suspected sepsis onset\n5. pre-hospitalization bedridden performance status (WHO\u002FZubrod score ≥4)\n6. subsequent clinical adjudication diagnosis not consistent with sepsis\u002Fseptic shock by Sepsis-3 criteria.\n7. Burn injury greater than 20% total body surface area (tBSA)\n\nTrauma Participant:\n\nInclusion Criteria\n\n1. All adults age ≥ 18 years\n2. Blunt trauma patient with a. Injury Severity Score (ISS) greater than or equal to 25 b. ISS \\> 15 and one of the following: i. \\> 4 units of PRBC or \\>3 units of whole blood or \\>1500 ml of autogenous blood product in the first 24 hours of admission ii. AIS (acute injury score) \\> 2 spine iii. Shock on arrival (Systolic blood pressure (SBP) \\\u003C 90)\n\nOR\n\nc. ISS \\> 15 and two of the following: i. Age \\> 55 ii. AIS \\> 2 chest iii. +ETOH (ethyl alcohol) on arrival iv. Any red blood cell transfusion in first 24 hours\n\nExclusion Criteria\n\n1. Patients not expected to survive greater than 48 hours.\n2. Prisoners.\n3. Pregnancy.\n4. Previous bone marrow transplantation.\n5. Patients with End Stage Renal Disease.\n6. Patients with any pre-existing hematological disease.\n7. Patients deemed to be futile care or have advanced directives limiting resuscitative efforts.\n8. Known HIV infection with CD4+ count \\\u003C200 cells\u002Fmm3\n9. Burn injury greater than 20% tBSA",{"count":58,"type":20},"Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.",[64,26],{"date":362,"type":40},{"date":380,"type":40},"2022-01-04",{"date":382,"type":20},"2027-04",{"name":276,"class":47},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":16,"minAge":284,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":21,"phases":394,"briefSummary":395,"conditions":396,"keywords":403,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":48},"100613601","assess-the-efficacy-of-tailored-patient-information-and-voluntary-patient-managed-outpatient-digital-follow-up-i-pod-as-an-adjunct-to-standard-treatment-according-to-national-guidelines-in-the-national-trauma-plan-among-adult-trauma-patients-in-norway-100613601","NCT07268716","Assess the Efficacy of Tailored Patient Information and Voluntary Patient-managed Outpatient Digital Follow-up (I-POD) as an Adjunct to Standard Treatment According to National Guidelines in the National Trauma Plan Among Adult Trauma Patients in Norway.","A Randomized Controlled Clinical Trial to Assess the Efficacy of Tailored Patient Information and Voluntary Patient-Managed Outpatient Digital Follow-Up as an Adjunct to Standard Treatment According to National Guidelines in Adult Trauma Patients in Norway (The POSTRAUMA Trial).","POSTRAUMA","Inclusion Criteria:\n\n* 16 years or older\n* Fulfils the national criteria for TTA and admitted to HUS following trauma\n* Included in NTR database\n* Able to give informed consent\n\nExclusion Criteria:\n\n* 15 years or younger\n* Not included in NTR database\n* Deceased before discharge from the hospital.\n* Not able to give informed consent\n* Insufficient command of the Norwegian language\n* Foreign tourists or nationals\n* Suicide attempt or serious self-inflicted trauma\n* Serious psychiatric disorders or serious ongoing substance abuse",{"count":393,"type":20},256,[23],"The POSTRAUMA trial is a clinical trial at The Regional trauma centre of Western Norway, Haukeland University Hospital.\n\nTrauma is the leading cause of death worldwide in patients aged 1-45 years. In Norway, approximately 10,000 patients are admitted to hospital annually due to trauma, with 66% being male. The mean age is 43 years for male and 48 years for female, indicating a relatively young patient population.\n\nWhile mortality rates are decreasing, a significant proportion of trauma survivors experience long-term disabilities, reduced quality of life, and difficulties in returning to work. These consequences impose substantial burdens on individuals, families, and society. Considering these issues, a shift in focus is needed-from survival alone to long-term functional recovery and quality of life after trauma.\n\nSevere trauma often requires long-term follow-up, both physically and psychosocially. Traditional follow-up can be fragmented and not tailored to individual needs. Digital patient monitoring and tailored information have the potential to improve patient pathways, but knowledge about how these are experienced by patients is limited.\n\nThe goal is to find out if Norwegian trauma patients who receive tailored patient information and patient-managed outpatient digital follow-up, in addition to standard treatment have:\n\n* Less disability\n* Return more often to work\n* Improved quality of life\n\nThe study population are Norwegian trauma patients, 16 years or older at date of inclusion, who are admitted to Haukeland University hospital (HUS) following trauma with trauma team activation. 256 patients will be included in this trial.\n\nParticipants will:\n\n* Answer a questionnaire at inclusion, one month, 6 months and 12 months.\n* Participants in the intervention group will be invited to digital outpatient follow up one month after the accident.\n* Some participants will be interviewed about how they experienced their trauma follow up.",[397,95,92,26,398,399,400,401,402],"Trauma Centers","Rehabilitation After Neurological or Orthopaedic Injuries","Rehabilitation","Return to Work","HRQOL (Health Related Quality Of Life)","EQ5D5L-VAS",[404,405,406,407,408,409],"multitrauma","trauma","rehabilitation","return to work","HRQOL","EQ5D","2025-12-16",{"date":412,"type":40},"2025-12-22",{"date":414,"type":20},"2026-03-02",{"date":416,"type":20},"2029-12-31",{"name":418,"class":47},"Haukeland University Hospital",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":16,"minAge":427,"maxAge":145,"enrollmentInfo":428,"targetDuration":4,"studyType":21,"phases":430,"briefSummary":431,"conditions":432,"keywords":436,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":4},"100392231","phase-3-traumatic-injury-clinical-trial-evaluating-tranexamic-acid-in-children-an-efficacy-study-100392231","NCT04387305","Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study","Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study","TIC-TOC","Inclusion Criteria:\n\n1. Less than 18 years old AND\n2. Penetrating torso trauma, blunt torso trauma, or head trauma as defined below:\n3. Penetrating Torso Trauma:\n\n   a. Penetrating trauma to the chest, abdomen, neck, or pelvis with at least one of the following:\n   * age-adjusted hypotension, or\n   * age-adjusted tachycardia despite adequate resuscitation fluids, or\n   * radiographic evidence of internal hemorrhage, or\n   * clinician suspicion of ongoing internal hemorrhage\n4. Blunt Torso Trauma:\n\n   1. Clinician suspicion of hemorrhagic blunt torso injury and at least one of the following:\n\n      * age-adjusted hypotension, or\n      * age-adjusted tachycardia despite adequate resuscitation fluids\n   2. Hemothorax on chest tube placement or imaging,\n   3. Clinical suspicion of hemorrhagic blunt torso injury and Intraperitoneal fluid on abdominal ultrasonography (Focused Assessment with Sonography in Trauma),\n   4. Intra-abdominal injury on CT with either contrast extravasation or more than trace intraperitoneal fluid,\n   5. Pelvic fracture with contrast extravasation or hematoma on abdominal\u002Fpelvic CT scan with at least one of the following:\n\n      * Age-adjusted hypotension, or\n      * Age-adjusted tachycardia.\n5. Head Trauma:\n\n   1. Initial Glasgow Coma Scale (GCS) score 3 to 13 with associated intracranial hemorrhage on cranial CT scan (enroll after cranial CT scan)\n\nExclusion Criteria:\n\n* Unable to administer study drug within 3 hours of traumatic event\n* Known pregnancy\n* Known ward of the state\n* Cardiac arrest prior to randomization\n* GCS score of 3 with bilateral unresponsive pupils\n* Isolated subarachnoid hemorrhage, epidural hematoma, or diffuse axonal injury\n* Known venous or arterial thrombosis\n* Known bleeding\u002Fclotting disorders\n* Known seizure disorders\n* Known history of severe renal impairment\n* Known allergy to TXA\n* Unknown time of injury (includes suspected non-accidental trauma)\n* Previous enrollment into the TIC-TOC trial\n* Prior TXA for current injury\n* Prior opt-out\n* Non-English and non-Spanish speaking","0 Years",{"count":429,"type":20},2000,[149],"Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and\u002For torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.",[433,434,435,26],"Brain Injuries, Traumatic","Wounds and Injury","Hemorrhage",[437,438,435,439,154,440,97],"Tranexamic acid","Brain Injuries","Clinical Trial","Pediatric","2025-12-09",{"date":443,"type":40},"2025-12-15",{"date":445,"type":20},"2026-10-01",{"date":447,"type":20},"2031-03-31",{"name":449,"class":47},"Daniel Nishijima, MD, MAS",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":458,"targetDuration":4,"studyType":21,"phases":460,"briefSummary":461,"conditions":462,"keywords":468,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":48},"100505741","ultrasound-guided-percutaneous-intercostal-nerve-cryoneurolysis-for-analgesia-following-traumatic-rib-fracture-100505741","NCT05865327","UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture","UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture, a Pilot Randomized Control Trial (UNPIN Trial)","UNPIN","Inclusion Criteria:\n\n* Aged ≥18\n* Unilateral traumatic rib fractures (3 to 8)\n* Candidate for ESP block catheter\n* Within 48hrs of admission to hospital\n\nExclusion Criteria:\n\n* Lack of patient consent; unlikely to comply with follow up\n* Unable to use Patient Controlled Regional Analgesia (Ventilated\u002Fsedated patients or Moderate to severe traumatic brain injury)\n* Chronic pain (opioid use \\> 30mg oral morphine equivalent per day)\n* Substance use disorder\n* CrCl \\\u003C 50\n* BMI \\> 45\n* Significant distracting injuries (unreduced long bone fractures, unstable pelvic or spine fractures and patients requiring trauma laparotomy- also preclude positioning for block placement (lateral decubitus or sitting up))\n* Contraindications for ESP catheter placement (pre-existing medical\u002Fneurological\u002Fhematologic diseases, localized infection\u002Ftrauma at site of intervention, allergy to amide local anesthetics)\n* Contraindications to CN (cryoglobulinemia, paroxysmal cold hemoglobinuria, multiple myeloma and cold urticarial).\n* Unable to return to Trauma Recovery Clinic (in-person or virtual) at 3 months",{"count":459,"type":20},24,[23],"Traumatic rib fractures (i.e., broken ribs caused by a physical injury) are common and very painful. They also often lead to serious complications, more time spent in hospital, and can even lead to death. Even after rib fractures have healed, they can lead to long-term pain and a lower quality of life.\n\nA technology called cryoneurolysis, which acts to freeze nerves causing pain using a small tool which can turn very cold, is a promising new way to manage rib fracture pain. This study is a test with a small number of people to see if it is feasible to use this technology for patients with rib fractures. If this is successful, we will recruit more people for a larger study to see if cryoneurolysis, along with standard pain control techniques, is better at stopping pain, compared to just the normal techniques alone. Participants in our study will be asked to rate their pain, and record pain medications that they take for 3 months after their pain procedure.",[463,464,465,30,466,467,97,26],"Rib Fractures","Rib Fracture Multiple","Rib; Fracture, With Flail Chest","Pain, Acute","Pain, Chronic",[469,470,471],"Cryoneurolysis","Rib Fracture Pain","Intercostal Nerve Block","2025-09-05",{"date":474,"type":40},"2025-09-12",{"date":476,"type":40},"2023-10-23",{"date":478,"type":20},"2025-12",{"name":480,"class":47},"Sunnybrook Health Sciences Centre",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":491,"conditions":492,"keywords":497,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":48},"100598499","relieved-regional-anesthesia-pelvic-fractures-study-study-regional-anesthesia-ra-techniques-for-pain-management-in-pelvic-fractures-a-prospective-monocentric-pilot-cohort-study-100598499","NCT07072286","RELIEVED (REgionaL anesthesIa PElVic fracturEs stuDy) Study. Regional Anesthesia (RA) Techniques for Pain Management in Pelvic Fractures: A Prospective, Monocentric, Pilot Cohort Study.","RELIEVED (REgionaL anesthesIa PElVic fracturEs stuDy) Study. Regional Anesthesia (RA) Techniques for Pain Management in Pelvic Fractures: A Prospective, Monocentric, Pilot Cohort Study. Pain Management in Surgical and Conservative Settings.\"","RELIEVED","Inclusion Criteria:\n\n* Age ≥ 18 years and ability to provide informed consent\n* Patients with pelvic\u002Facetabular fractures requiring surgery\n\nExclusion Criteria\n\n* Age \\\u003C 18 years\n* Absolute contraindications to ALR techniques (uncorrectable coagulopathies, known allergy to local anesthetics, technical impossibility of execution)",{"count":490,"type":20},200,"The goal of this observational clinical trial is to assess the impact of Regional Anesthesia (RA) techniques with the strongest anatomical and scientific support in controlling acute post-operative pain in pelvic\u002Facetabular fractures, as well as their potential role in reducing complications related to excessive intra- and postoperative opioid use.\n\nThe main questions it aims to answer are:\n\nDoes RA lower opioid use in the first 24 hours after pelvic\u002Facetabular fractures surgery? Does RA lower pain scores in the first 48 hours after surgery, incidence of complications and occurrence of persistent post-surgical pain?\n\nDuring the hours and days following surgery, the research team will evaluate and assess the intensity of any postoperative pain at predefined time points; quantify the use of pain medications and any related complications; and measure the possible onset of chronic pain and the timeline of functional recovery (through scheduled clinical follow-up at 30, 60, and 90 days).\n\nParticipants will:\n\nat the time of surgery, and only in the presence of trained and certified anesthesiologists, patients will receive regional anesthesia techniques in addition to the standard multimodal analgesic treatment. In the absence of certified anesthesiologists, patients will be treated exclusively with systemic multimodal analgesia according to the standard protocol.\n\nAll the procedures are part of the current clinical practice and no experimental techniques or medications are involved.",[493,494,495,496,26],"Pelvic Bone Injury","Pelvis Injury","Acetabular Fractures","Acetabular Surgery",[498,499,500,501,502],"regional anethesia","pain management","pelvic fractures","acetabular fractures","surgery","2025-07-09",{"date":505,"type":40},"2025-07-18",{"date":507,"type":40},"2024-07-25",{"date":509,"type":20},"2026-09-25",{"name":511,"class":47},"A.O.U. Città della Salute e della Scienza",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":48},"100499586","oct-in-open-fracture-and-infected-fracture-100499586","NCT05785182","OCT in Open Fracture and Infected Fracture","Optical Coherence Tomography Imaging to Visualize Bacteria or Biofilm on Hardware, Bone and Soft Tissue in Open Fracture and Infected Fracture","Inclusion Criteria:\n\n* Age 18 years or older\n* Open fracture\n* Fracture Related Infection\n\nExclusion Criteria:\n\n* Metatarsal fractures",{"count":520,"type":20},40,"This is a pilot prospective, observational study of patients with open or infected fracture evaluating the feasibility and acceptability of OCT, a light-based imaging modality that requires no drug or contrast agent.",[26,97,523,524],"Open Fracture","Fracture Infection","2025-06-24",{"date":527,"type":40},"2025-06-27",{"date":529,"type":40},"2023-03-27",{"date":190,"type":20},{"name":248,"class":47},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":328,"sex":16,"minAge":540,"maxAge":4,"enrollmentInfo":541,"targetDuration":543,"studyType":89,"phases":4,"briefSummary":544,"conditions":545,"keywords":547,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":48},"100596545","predictive-accuracy-of-plr-and-pnr-in-detecting-etic-100596545","NCT07046858","Predictive Accuracy of PLR and PNR in Detecting ETIC","Predictive Accuracy of Platelet Lymphocyte Ratio & Platelet Neutrophil Ratio in Detecting Early Trauma Induced Coagulopathy","ETIC","Inclusion Criteria:\n\n* All patients with trauma AND\n* Presenting to ED within 6 hours of the event AND\n* The ED Physician sends coagulation profile\n\nExclusion Criteria:\n\n* Treated with intravenous fluids, drugs, whole blood and blood products elsewhere\n* Patients admitted with a non-mechanical mechanism of injury, specifically drowning, hanging,or burns, as these mechanisms may result in a different biologic response than mechanical trauma\n* Patients on known medications affecting coagulation profile or hemogram\n* Patients with known chronic liver disease, chronic renal failure, malignancy, hematological disorders\n* Patients not consenting for the study","12 Years",{"count":542,"type":20},250,"1 Day","Observational study to know what is the predictive accuracy of platelet-neutrophil ratio (PNR) and platelet-lymphocyte ratio (PLR) done in patients presenting to ED( emergency department)within 6 hours of trauma; in detecting early trauma induced coagulopathy during hospital admission",[26,546],"Coagulopathy",[548],"Early trauma induced coagulopathy","2025-06-23",{"date":551,"type":40},"2025-07-02",{"date":553,"type":40},"2023-10-17",{"date":555,"type":20},"2025-11-27",{"name":557,"class":47},"Jubilee Mission Medical College and Research Institute",{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":21,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":48},"100582067","bioimpedance-for-ortho-trauma-100582067","NCT06858488","Bioimpedance for Ortho Trauma","A Pilot Study on the Technical Feasibility of an Electrical Impedance Tomography Device for Soft Tissue Injury Following High Energy Extremity Fractures","Inclusion Criteria:\n\n* Age 18 years or older\n* High energy closed extremity fracture\n* Provision of informed consent\n\nExclusion Criteria:\n\n* Metatarsal fractures\n* Injury to both lower extremities precluding contralateral imaging\n* Presence of an implanted electronic device (e.g. pacemaker, vagal stimulator, deep brain stimulator) or electrodes or electrical wires.\n* Currently pregnant, potentially pregnant, or lactating women",{"count":5,"type":20},[23],"Patients with high-energy extremity trauma will undergo imaging with an EIT device in the Emergency Department, Operating Room, Orthopaedic Clinic, and In-patient hospital rooms. The EIT device is an electrical impedance tomography system.",[26],[570,571],"Orthopedics","Extremity fracture","2025-06-17",{"date":574,"type":40},"2025-06-22",{"date":576,"type":40},"2025-03-20",{"date":190,"type":20},{"name":248,"class":47},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":21,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":48},"100487976","phase-3-whole-blood-in-trauma-patients-with-hemorrhagic-shock-100487976","NCT05634109","Whole Blood in Trauma Patients With Hemorrhagic Shock","Whole Blood vs. Blood Components Therapy in the Hemostatic Resuscitation of Severe Trauma Patients: An Open-label, Randomized, Controlled Clinical Trial","WEBSTER","Inclusion Criteria:\n\n* Adult patients (\\> 18 years)\n* Activating institutional trauma code for trauma patients with hemorrhagic shock.\n* Candidate for massive transfusion (Patient with an Assessment Blood Consumption (ABC) Score ≥ 2 or at the discretion of the treating physician)\n* Concurrent availability of whole blood or blood component therapy\n\nExclusion Criteria:\n\n* More than 4 hours from trauma to hospital admission\n* More than 2 hours from hospital admission to randomization\n* Transfusion of more than one packed red blood cell unit prior to randomization.\n* Patients who have undergone surgery (laparotomy, thoracotomy, or sternotomy) before hospital admission.\n* In-extremis patients with devastating injuries (expected to die within 60 minutes).\n* Blood group other than to O or A and positive Rh factor\n* Severe traumatic brain injury in which neurosurgical intervention is futile (partial decapitation, massive intracranial hemorrhage, or transcranial gunshot wounds).\n* Burns over 20% of the total body surface area.\n* Suspected airway burn.\n* Cardiopulmonary resuscitation (CPR) before arrival at the ED.\n* CPR for more than 5 minutes before randomization.\n* Do not resuscitate order.\n* Incarcerated\u002Fprisoners.\n* Known pregnancy in the ED.\n* Patient or legal representative who refuse to participate in clinical research studies.",{"count":588,"type":20},220,[149],"This study aims to evaluate among trauma patients with hemorrhagic shock the clinical impact of hemostatic resuscitation between whole blood vs. blood components therapy in the following outcomes in a hierarchical analysis: mortality at 28 days and evolution of organ dysfunction.",[97,26,592],"Trauma, Multiple",[594,595,596,435,597,598],"whole blood","Blood Transfusion","Blood Component Transfusion","Advanced Trauma Life Support Care","Hemostatic resuscitation","2025-02-24",{"date":601,"type":40},"2025-02-27",{"date":603,"type":40},"2023-01-14",{"date":605,"type":20},"2026-03",{"name":607,"class":47},"Fundacion Clinica Valle del Lili",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":614,"enrollmentInfo":615,"targetDuration":4,"studyType":21,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":627,"locationsCount":4},"100554770","a-prospective-study-using-suprasdrm-in-promoting-healing-and-reducing-the-time-to-grafting-of-full-thickness-wounds-100554770","NCT06503406","A Prospective Study Using SupraSDRM® in Promoting Healing and Reducing the Time to Grafting of Full-thickness Wounds","Inclusion Criteria:\n\n* Patient age ≥18 years and ≤85 years\n* Full-thickness traumatic injury, surgical wound, or excised full-thickness burn (e.g., friction, contact, flame, scalding etiology), where immediate grafting is not deemed suitable by the treating surgeon\n* Wound size ≥ 5cm2 not immediately suitable for graft application\n* Subject or legally authorized representative is able and willing to sign informed consent\n\nExclusion Criteria:\n\n* Study wound may not include areas of the face, and neck and genitalia.\n* Wound with metal hardware exposure\n* Pressure sores\n* Wounds with residual malignancy\n* Wound infection at the time of planned wound dressing application\n* Wound that is a part of an active treatment arm of an interventional study (within 90 days of Screening Visit)\n* Pregnancy\u002Flactation\n* Subjects who are unable to follow the protocol or who are likely to be non-compliant\n* Subjects with uncontrolled diabetes (defined by Hgb A1C \\>10)\n* Subjects who are receiving systemic steroids or immune suppressive treatment\n* Subject with a known allergy to polylactide, polycaprolactone, polyvinyl alcohol, trimethylene carbonate or resorbable suture materials.\n* Prisoners","85 Years",{"count":459,"type":20},[23],"This is a prospective, randomized, controlled, multi-center clinical study comparing SupraSDRM® to standard of care wound dressing, BTM, in the treatment of full-thickness wounds deemed not immediately suitable for definitive grafting will be performed.",[619,620,26],"Surgical Wound","Burns","2025-02-19",{"date":623,"type":40},"2025-02-21",{"date":625,"type":20},"2025-03",{"date":219,"type":20},{"name":628,"class":47},"The Metis Foundation",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":614,"enrollmentInfo":636,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":638,"conditions":639,"keywords":642,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":655,"leadSponsor":657,"locationsCount":4},"100541205","inoss-mbcp-putty-ortho-100541205","NCT06326827","In'Oss™ (MBCP® Putty) Ortho","Study of the Osteoconductive Potential of the Injectable Bone Substitute In'Oss™ (MBCP® Putty) in the Filling of Orthopaedic Bone Defects","Inclusion Criteria:\n\n1. Patient is male or female, 18 - 85 years old;\n2. Patient is willing and able to give written informed consent;\n3. Patient is able to comply with a prior medical examination;\n4. Patient is or has been scheduled for a surgical procedure to correct epiphyso-metaphyseal and\u002For metaphyso-diaphyseal bone defect in one of the following anatomical locations:\n\n   * Proximal humerus ▪ Distal radius\n   * Distal femur ▪ Proximal tibia ▪ Distal tibia\n5. Patient is willing and able to comply with the study procedures during surgery and the post-surgical follow up period, up to 12 months.\n\nExclusion Criteria:\n\n1. Patient has had an infection in the same extremity within last 24 months;\n2. Patient has signs of necrosis at the surgical site;\n3. Patient has cellulitis;\n4. Patient has granuloma or non-curetted cyst;\n5. Patient has an history of uncontrolled diabetes;\n6. Patient is alcoholic and\u002For heavy smoker (\\> 20 cigarettes per day);\n7. Patient has a congenital or acquired immunodeficiency;\n8. Patient has severe bone loss (≥ 40cm3);\n9. Patient is on long-term steroidal therapy or treatment acting on the calcium or phosphorus metabolism;\n10. Patient is or has been scheduled for surgery that would involve intra-articular implantation of the study device;\n11. Patient who has or had an uncontained bone defect created as a result of trauma injury or surgically created;\n12. Patient was exposed to any radiation (e.g. X-Rays, handling of radiolabelled materials) other than the normal background radiation within the 12 months before the screening visit;\n13. Patient is pregnant;\n14. Patient who is an employee at the study site;\n15. Patient is known to be non-compliant with medical treatment or follow-up\n16. Patient has any significant or unstable medical\u002Fpsychiatric condition that, in the opinion of the Investigator, would interfere with their ability to participate in the study;\n17. Patient is currently enrolled or planning to enrol in another clinical study or treatment with another investigational drug\u002Fdevice that may interfere with the assessments, visits or outcomes of this study.",{"count":637,"type":20},100,"Study of the osteoconductive potential of the injectable bone substitute In'Oss™ (MBCP® Putty) in the filling of orthopaedic bone defects to collect Post-Market Clinical Follow-up (PMCF) data for the CE-marked In'Oss™ (MBCP® Putty) device in the orthopaedic trauma surgery",[640,26,641],"Orthopedic Disorder","Extremity Injury",[643,644,645,646,647,648,649,650],"Proximal humerus","Distal radius","Distal femur","Proximal tibia","Distal tibia","Fracture","MBCP Putty","Bone defect reconstruction","2025-02-03",{"date":653,"type":40},"2025-02-05",{"date":625,"type":20},{"date":656,"type":20},"2027-03",{"name":658,"class":659},"Advanced Medical Solutions Ltd.","INDUSTRY",{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":669,"conditions":670,"keywords":671,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":685},"100554069","how-many-patients-suffering-major-trauma-would-be-eligible-for-a-pre-hospital-transfusion-100554069","NCT06494293","How Many Patients Suffering Major Trauma Would be Eligible for a Pre-hospital Transfusion","How Many Patients Suffering Major Trauma Would be Eligible for a Pre-hospital Transfusion: A Multicentre Retrospective Study.","TRAP","Inclusion Criteria :\n\n* Patients over 18\n* Taken care of by a MICU team from participating centres\n* Victims of major trauma requiring transport to an emergency\u002Frecovery unit or declared dead during care\n* Informed and did not object to the collection of his data for research purposes during his lifetime\n\nExclusion Criteria :\n\n* Traumatological reason for departure not confirmed in the emergency medical services report\n* Patient care of by the MICU for secondary transport (transport from one hospital to another)\n* Patient died without resuscitation by a professional\n* Patient with manifest isolated closed head injury\n* Patient deprived of civil rights",{"count":490,"type":20},"The aim of the study is to measure the number of patients being cared for by a medical team for major trauma who could benefit from a transfusion labile blood products and thus provide a scientific argument in favour of supplying labile blood products to pre-hospital",[26],[672,673,674,675],"Major trauma","Mobile Intensive Care Unit (MCIU)","Out of hospital emergency care","Blood transfusion","2024-12-30",{"date":678,"type":40},"2024-12-31",{"date":680,"type":20},"2025-04",{"date":682,"type":20},"2025-05",{"name":684,"class":47},"Hôpital NOVO",4]